Fiche publication
Date publication
septembre 2023
Journal
Oncoimmunology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François
,
Dr THIBAUDIN Marion
Tous les auteurs :
Thibaudin M, Ghiringhelli F
Lien Pubmed
Résumé
Checkpoint blockade immunotherapy transforms many types of cancer; however, in the field of metastatic colorectal cancer, checkpoint blockers are only effective in microsatellite-unstable tumors, which represent only a minority of patients. Microsatellite-stable tumors are thought to be immunoresistant. A recent publication demonstrates that, contrary to the standard view point, the combination of chemo-immunotherapy could trigger a tumor-specific immune response, leading to clinical benefit.
Mots clés
Checkpoint blockade, clinical trial, colorectal cancer, immunogenic cell death
Référence
Oncoimmunology. 2023 09 15;12(1):2257098
